Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Reshape Lifesciences Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Reshape Lifesciences's (NASDAQ:RSLS) reported sales totaled $2.44 million. Despite a 76.83% increase in earnings, the company posted a loss of $8.21 million. Reshape Lifesciences collected $3.14 million in revenue during Q4, but reported earnings showed a $35.46 million loss.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.